Tiziana reports encouraging Expanded Access data for Foralumab in MS patients

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to discuss updated clinical findings from the company’s ongoing Expanded Access Program evaluating intranasal foralumab in patients living with non-active Secondary Progressive Multiple Sclerosis (SPMS). The newly released data, updated through March 2026 and reflecting patient outcomes from 14 individuals, continue to support the therapy’s safety profile while also demonstrating signs of meaningful clinical benefit. Elrifi explained that patients receiving intranasal foralumab have continued to tolerate the treatment well over extended periods, with no new safety concerns emerging during the evaluation period. The updated findings suggest encouraging trends toward stabilization of disability progression, an important consideration for patients with SPMS, where treatment options remain limited and disease progression can significantly impact quality of life. The company highlighted that disability was asses...